Summary | |
---|---|
Symbol | ILF2 |
Name | interleukin enhancer binding factor 2 |
Aliases | NF45; interleukin enhancer binding factor 2, 45kD; interleukin enhancer binding factor 2, 45kDa; PRO3063; nu ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus, nucleolus. Cytoplasm. Nucleus. Note=Localized in cytoplasmic mRNP granules containing untranslated mRNAs. |
Domain |
PF07528 DZF domain |
Function |
Appears to function predominantly as a heterodimeric complex with ILF3. This complex may regulate transcription of the IL2 gene during T-cell activation. It can also promote the formation of stable DNA-dependent protein kinase holoenzyme complexes on DNA. Essential for the efficient reshuttling of ILF3 (isoform 1 and isoform 2) into the nucleus. |
Biological Process | - |
Molecular Function |
GO:0003725 double-stranded RNA binding |
Cellular Component | - |
KEGG | - |
Reactome |
R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-6798695: Neutrophil degranulation |
Summary | |
---|---|
Symbol | ILF2 |
Name | interleukin enhancer binding factor 2 |
Aliases | NF45; interleukin enhancer binding factor 2, 45kD; interleukin enhancer binding factor 2, 45kDa; PRO3063; nu ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ILF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | ILF2 |
Name | interleukin enhancer binding factor 2 |
Aliases | NF45; interleukin enhancer binding factor 2, 45kD; interleukin enhancer binding factor 2, 45kDa; PRO3063; nu ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ILF2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ILF2 |
Name | interleukin enhancer binding factor 2 |
Aliases | NF45; interleukin enhancer binding factor 2, 45kD; interleukin enhancer binding factor 2, 45kDa; PRO3063; nu ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ILF2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of ILF2 in various data sets.
|
Summary | |
---|---|
Symbol | ILF2 |
Name | interleukin enhancer binding factor 2 |
Aliases | NF45; interleukin enhancer binding factor 2, 45kD; interleukin enhancer binding factor 2, 45kDa; PRO3063; nu ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ILF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ILF2 |
Name | interleukin enhancer binding factor 2 |
Aliases | NF45; interleukin enhancer binding factor 2, 45kD; interleukin enhancer binding factor 2, 45kDa; PRO3063; nu ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ILF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ILF2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ILF2 |
Name | interleukin enhancer binding factor 2 |
Aliases | NF45; interleukin enhancer binding factor 2, 45kD; interleukin enhancer binding factor 2, 45kDa; PRO3063; nu ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ILF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ILF2 |
Name | interleukin enhancer binding factor 2 |
Aliases | NF45; interleukin enhancer binding factor 2, 45kD; interleukin enhancer binding factor 2, 45kDa; PRO3063; nu ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ILF2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ILF2 |
Name | interleukin enhancer binding factor 2 |
Aliases | NF45; interleukin enhancer binding factor 2, 45kD; interleukin enhancer binding factor 2, 45kDa; PRO3063; nu ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ILF2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | ILF2 |
Name | interleukin enhancer binding factor 2 |
Aliases | NF45; interleukin enhancer binding factor 2, 45kD; interleukin enhancer binding factor 2, 45kDa; PRO3063; nu ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting ILF2 collected from DrugBank database. |
There is no record. |